A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

por Nygaard, Haakon B, Wagner, Allison F, Bowen, Garrett S, Good, Susan P, MacAvoy, Martha G, Strittmatter, Kurt A, Kaufman, Adam C, Rosenberg, Brian J, Sekine-Konno, Tomoko, Varma, Pradeep, Chen, Kewei, Koleske, Anthony J, Reiman, Eric M, Strittmatter, Stephen M, van Dyck, Christopher H
Publicado 2015

In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET

por Mecca, Adam P., Chen, Ming‐Kai, O'Dell, Ryan S., Naganawa, Mika, Toyonaga, Takuya, Godek, Tyler A., Harris, Joanna E., Bartlett, Hugh H., Zhao, Wenzhen, Nabulsi, Nabeel B., Wyk, Brent C. Vander, Varma, Pradeep, Arnsten, Amy F. T., Huang, Yiyun, Carson, Richard E., van Dyck, Christopher H.
Publicado 2020